Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?

机译：复发性难治性多发性骨髓瘤的治疗：患者偏爱哪种新的基于PI的联合治疗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and objectivesThis study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.

机译：背景和目的本研究描述了基于新型蛋白酶体抑制剂的联合治疗对德国复发性难治性多发性骨髓瘤（RRMM）患者的偏好。

著录项

期刊名称 Patient preference and adherence
作者
Thomas Wilke; Sabrina Mueller; Sabine Bauer; Silvia Pitura; Leona Probst; Boris A Ratsch; Hans Salwender;
展开▼
作者单位

展开▼
年(卷),期 2018(12),-1
年度 2018
页码 2387–2396
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词
MM patient’s treatment preferences relapsed refractory multiple myeloma RRMM discrete choice experiment DCE;

机译：MM患者的治疗偏好;难治性多发性骨髓瘤复发;RRMM;离散选择实验;DCE;

相似文献

外文文献
中文文献
专利

1. Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? [J] . Thomas Wilke, Sabrina Mueller, Sabine Bauer, Patient Preference and Adherence . 2018,第1期

机译：复发性难治性多发性骨髓瘤的治疗：患者偏爱哪种新的基于PI的联合治疗？
2. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. [J] . Richardson PG, Chanan Khan AA, Lonial S, British Journal of Haematology . 2011,第6期

机译：Tanespimycin和bortezomib联合治疗复发或复发且难治性多发性骨髓瘤的患者：1/2期研究的结果。
3. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study [J] . Paul G. Richardson, Asher A. Chanan-Khan, Sagar Lonial, British Journal of Haematology . 2011,第6期

机译：Tanespimycin和bortezomib联合治疗复发性或复发性和难治性多发性骨髓瘤患者：1/2期研究结果
4. Outcomes of combination treatments in refractory neovascular glaucoma. A retrospective review in patients with advanced proliferative diabetic retinopathy [C] . Ramoa R., Juberfas J.R., Manzanas L, International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：难治性新生血管青光眼组合治疗的结果。晚期增殖性糖尿病视网膜病变患者的回顾性综述
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation [O] . Rūta Čepulytė, Andrius Žučenka, Valdas Pečeliūnas 2020

机译：Dabrafenib和Trametinib的组合治疗复发和难治性多发性骨髓瘤遍布BRAF v600E突变
7. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor [O] . Samantha Hinsley, Katrina Walker, Debbie Sherratt, 2020

机译：MUK 8方案：环磷酰胺和地塞米松的随机期II试验与Ixazomib，复发或难治性多发性骨髓瘤（RRMM）患者与亚马亚度胺，Lenalidomide和蛋白酶体抑制剂进行处理后复发

Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?

摘要

著录项

相似文献

相关主题

期刊订阅